Longer Survival and Preserved Liver Function after Proton Beam Therapy for Patients with Unresectable Hepatocellular Carcinoma

被引：2

作者：

Nosaka, Takuto ^{[1
]}

Matsuda, Hidetaka ^{[1
]}

Sugata, Ryotaro ^{[1
]}

Akazawa, Yu ^{[1
]}

Takahashi, Kazuto ^{[1
]}

Naito, Tatsushi ^{[1
]}

Ohtani, Masahiro ^{[1
]}

Kinoshita, Kazuyuki ^{[2
]}

Tsujikawa, Tetsuya ^{[2
]}

Sato, Yoshitaka ^{[3
]}

Maeda, Yoshikazu ^{[3
]}

Tamamura, Hiroyasu ^{[3
]}

Nakamoto, Yasunari ^{[1
]}

机构：

[1] Univ Fukui, Fac Med Sci, Dept Internal Med 2, Fukui 9101193, Japan

[2] Univ Fukui, Fac Med Sci, Dept Radiol, Fukui 9101193, Japan

[3] Fukui Prefecture Hosp, Proton Therapy Ctr, Fukui 9108526, Japan

来源：

CURRENT ONCOLOGY | 2023年 / 30卷 / 04期

关键词：

hepatocellular carcinoma; proton beam therapy; transcatheter arterial chemoembolization; radiofrequency ablation; albumin-bilirubin score; RADIOFREQUENCY ABLATION; TRANSARTERIAL CHEMOEMBOLIZATION; RADIOTHERAPY; PROGNOSIS; JAPAN;

D O I：

10.3390/curroncol30040296

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Proton beam therapy (PBT) has been recently reported to achieve excellent tumor control with minimal toxicity in patients with unresectable hepatocellular carcinoma (HCC). Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) was investigated for larger HCC. This study was designed to evaluate the therapeutic effect of PBT on unresectable HCC in comparison with TACE combined with RFA. Methods: We retrospectively analyzed 70 patients with HCC which was difficult to control by surgical resection or RFA monotherapy, 24 patients treated with PBT and 46 patients with TACE plus RFA. The therapeutic effects were assessed as local progression-free survival (PFS) and overall survival (OS). Results: The local PFS was more than 65% in 60 months for PBT and TACE plus RFA. The patients treated with PBT showed 82% OS at 60 months post-treatment. In contrast, those treated with TACE plus RFA showed 28% OS. When comparing the changes of ALBI scores in patients with different severities of chronic liver disease, the scores of PBT-treated patients were maintained at the baseline; however, those of TACE plus RFA-treated patients worsened after the treatments. Conclusions: The results indicated that PBT may show better benefits than TACE plus RFA therapy in terms of OS in patients with unresectable HCC by sparing the non-tumor liver tissues.

引用

页码：3915 / 3926

页数：12

共 32 条

[1] Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].